ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy.
The last earnings update was 7 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
ObsEva. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
ObsEva's earnings available for a low price, and how does
this compare to other companies in the same industry?
ObsEva is not considered high growth as it is expected to be loss making for the next 1-3 years.
ObsEva's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
ObsEva's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Ernest Loumaye, MD, PhD, OB/GYN Co-Founded ObsEva SA in November 2012 and has been its Chief Executive Officer since November 2012. Dr. Loumaye co-founded PregLem SA in 2006 and served as its Chief Executive Officer from 2006 to October 19, 2015. Dr. Loumaye has 9 years of experience as Head of Clinical Development for Reproductive Health (RH) at Serono in Geneva and Boston. He serves as Visiting Professor of Reproductive Endocrinology at Louvain University, Brussels. Dr. Loumaye served as Vice President of Medical Sciences, Endocrinology, Research & Development at Ipsen since 2003. Dr. Loumaye served as the Chairman of GenKyoTex S.A until December 21, 2016. He served as Chairman of PregLem SA. Dr. Loumaye serves as Member of PregLem’s Scientific Advisory Board. He serves as Director of ObsEva SA. He served as a Board Member of PregLem SA since 2006. He was a research fellow at the National Institute of Child Health and Human Development, in the US and is the author of over 90 publications in peer-reviewed journals. Dr. Loumaye holds a MD, PhD and OB/GYN degree from Louvain University, Belgium.
Insufficient data for Ernest to compare compensation growth.
Insufficient data for Ernest to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the ObsEva management team is about average.
Chief Financial Officer
Chief Scientific Officer and Head of R&D
Senior Director of Investor Relations
Chief Medical Officer & Head of Pharmacovigilance
Personal Assistant to the CSO and Head of R&D
Chief Commercial Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the ObsEva board of directors is about average.
Do Institutions Own ObsEva SA (NASDAQ:OBSV) Shares?
But other times, private equity is selling out, having taking the company public. … Private Company Ownership Our data indicates that Private Companies hold 4.3%, of the company's shares. … Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
Before You Buy ObsEva SA (NASDAQ:OBSV), Consider Its Volatility
Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.
How Much Of ObsEva SA (NASDAQ:OBSV) Do Insiders Own?
Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … ObsEva is a smaller company with a market capitalization of US$619m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company
How Financially Strong Is ObsEva SA (NASDAQ:OBSV)?
However, it also faces higher cost of capital given interest cost is generally lower than equity. … Does OBSV's growth rate justify its decision for financial flexibility over lower cost of capital. … Debt funding can be cheaper than issuing new equity due to lower interest cost on debt
Are You Backing The Right Horse With ObsEva SA (NASDAQ:OBSV)?
operates in the healthcare industry,. … This is illustrated by the growing pressure for innovative, cost-effective treatments, along with higher requirements for transparency from regulators and healthcare providers … Healthcare analysts are forecasting for the entire industry,
How Financially Strong Is ObsEva SA (NASDAQ:OBSV)?
The direct benefit for ObsEva SA (NASDAQ:OBSV), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … However, the trade-off is OBSV will have to adhere to stricter debt covenants and have less financial flexibility. … Does OBSV's growth rate justify its decision for financial flexibility over lower cost of capital
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.